



# Role of vitamin D in COVID-19 management

Samaneh Zandifar<sup>1</sup>

**Implication for health policy/practice/research/medical education:** Vitamin D plays an essential role in the management of COVID-19.

**Citation:** Zandifar S. Role of vitamin D in COVID-19 management. J Ren Endocrinol. 2023;9:e25091. doi: 10.34172/jre.2023.25091.

**Keywords:** COVID-19, Vitamin D, Vaccine, Management

**Copyright** © 2023 The Author(s); Published by Nickan Research Institute. This is an open-access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

COVID-19 is a subdivision of the beta coronavirus family which causes SARS-COV2 (1). Micronutrients like vitamins C and D affect the human immune system (2). Insufficient vitamin D is a worldwide issue that can be related to ethnicity, latitude, and age. Low vitamin D levels can be associated with conditions such as malignancy, hypertension, diabetes mellitus, and chronic respiratory and cardiac diseases (3).

Vitamin D attaches to the vitamin D response element (VDRE) and suppresses the adverse effects of COVID-19 by changing the innate and adaptive immunity, the renin-angiotensin system (RAS), and physical blockage (4). In animal models, it has been shown that vitamin D modifies RAS and angiotensin-converting enzyme 2 (ACE2) (5,6). These effects are essential as COVID-19 applies ACE2 to infect alveolar epitheliums (7,8). On the other hand, soluble ACE attaches to the COVID-19 S protein and prevents cells from infections; therefore, decreasing soluble ACE2 causes inflammation and adult respiratory distress syndrome (ARDS) (9).

In addition, vitamin D reduces proinflammatory cytokines like tumor necrosis factor-alpha (TNF- $\alpha$ ) and interferon-gamma (IFN- $\gamma$ ), which results in a reduction of ARDS risk (4). One of the innate antiviral elements is type I interferon (IFN 1), which can delay inflammatory response causing severe COVID-19 illness (9). Hypovitaminosis D can result in decreased IFN 1 due to a high level of VDRE (9). Additionally, vitamin D plays a crucial role in E-cadherin function, which influences tight junction against virus infiltration (4).

Some studies showed vitamin D could play a key role in COVID-19 treatment as a therapeutic adjuvant agent by improving the vaccine's efficacy (9). However, in another study, Chillon et al found no significant

association between mRNA vaccine response (through the generation of antibodies). Vitamin D status in healthy adults with medium-level vitamin D. This study has some limitations, including cellular immunity was not assessed. The sample population was adult healthcare workers (10). Taking vitamin D supplements is reasonable and safe for people with hypovitaminosis D to mitigate the COVID-19 infection risk by complementing the immune response to the vaccine through enhancement of antigen-presenting cells, CD4+T, and CD8+ T cells interactions (9). Although multiple studies showed vitamin D can affect the immune response to COVID-19 and vaccine efficiency, more studies are needed to delineate the role of vitamin D in COVID-19 management.

## Conflicts of interest

The author declares that she has no competing interests.

## Ethical issues

The author has completely observed ethical issues (including plagiarism, data fabrication, and double publication).

## Funding/Support

None.

## References

1. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020;395:507-513. doi: 10.1016/S0140-6736(20)30211-7.
2. Toscano GADS, de Araújo II, de Souza TA, Barbosa Mirabal IR, de Vasconcelos Torres G. Vitamin C and D supplementation and the severity of COVID-19: A protocol for systematic review and meta-analysis. *Medicine (Baltimore)*. 2021;100:e26427. doi: 10.1097/MD.00000000000026427.
3. Schleicher RL, Sternberg MR, Looker AC, Yetley EA, Lacher

- DA, Sempos CT, et al. National Estimates of Serum Total 25-Hydroxyvitamin D and Metabolite Concentrations Measured by Liquid Chromatography-Tandem Mass Spectrometry in the US Population during 2007-2010. *J Nutr*. 2016;146:1051-61. doi: 10.3945/jn.115.227728.
4. Annweiler C, Beaudenon M, Gautier J, Simon R, Dubée V, Gonsard J, et al; COVIT-TRIAL study group. COvid-19 and high-dose VITamin D supplementation TRIAL in high-risk older patients (COVIT-TRIAL): study protocol for a randomized controlled trial. *Trials*. 2020 Dec 28;21:1031. doi: 10.1186/s13063-020-04928-5.
  5. Kong J, Zhu X, Shi Y, Liu T, Chen Y, Bhan I, et al. VDR attenuates acute lung injury by blocking Ang-2-Tie-2 pathway and renin-angiotensin system. *Mol Endocrinol*. 2013;27:2116-25. doi: 10.1210/me.2013-1146.
  6. Yuan W, Pan W, Kong J, Zheng W, Szeto FL, Wong KE, et al. 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. *J Biol Chem*. 2007;282:29821-30. doi: 10.1074/jbc.M705495200.
  7. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*. 2020;181:271-280.e8. doi: 10.1016/j.cell.2020.02.052.
  8. Dijkman R, Jebbink MF, Deijs M, Milewska A, Pyrc K, Buelow E, et al. Replication-dependent downregulation of cellular angiotensin-converting enzyme 2 protein expression by human coronavirus NL63. *J Gen Virol*. 2012;93:1924-1929. doi: 10.1099/vir.0.043919-0.
  9. Chiu SK, Tsai KW, Wu CC, Zheng CM, Yang CH, Hu WC, et al. Putative Role of Vitamin D for COVID-19 Vaccination. *Int J Mol Sci*. 2021;22:8988. doi: 10.3390/ijms22168988.
  10. Chillon TS, Demircan K, Heller RA, Hirschbil-Bremer IM, Diegmann J, Bachmann M, Moghaddam A, Schomburg L. Relationship between Vitamin D Status and Antibody Response to COVID-19 mRNA Vaccination in Healthy Adults. *Biomedicines*. 2021;9:1714. doi: 10.3390/biomedicines9111714.